Medulloblastomas overexpress the p53-inactivating oncogene WIP1/PPM1D

Journal of Neuro-Oncology

Volumn 86, Issue 3, 2008, Pages 245-256

  Castellino, Robert C ^a   De Bortoli, Massimiliano ^a   Lu, Xiongbin ^a   Moon, Sung Hwan ^a   Nguyen, Thuy Ai ^a   Shepard, Mark A ^a   Rao, Pulivarthi H ^a   Donehower, Lawrence A ^a   Kim, John Y H ^a,b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b KAISER PERMANENTE   (United States)

Author keywords

Apoptosis; FISH; Isochromosome 17q; Medulloblastoma; p53; WIP1 PPM1D

Indexed keywords

ANTIINFECTIVE AGENT; ETOPOSIDE; ONCOPROTEIN; PROTEIN P53;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CARCINOGENESIS; CELL CYCLE REGULATION; CELL FRACTIONATION; CHILD; CHROMOSOME 17; CLINICAL ARTICLE; CYTOGENETICS; FEMALE; GENE AMPLIFICATION; GENE MUTATION; GENE OVEREXPRESSION; GENETIC TRANSFECTION; GENOTOXICITY; HUMAN; HUMAN CELL; HUMAN TISSUE; INFANT; MALE; MEDULLOBLASTOMA; MUTATION; ONCOGENE; PROTEIN ANALYSIS; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; TUMOR GENE; TUMOR SUPPRESSOR GENE;

ADOLESCENT; APOPTOSIS; CELL LINE, TUMOR; CHILD; CHILD, PRESCHOOL; CHROMOSOMES, HUMAN, PAIR 17; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GREEN FLUORESCENT PROTEINS; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; IN SITU NICK-END LABELING; INFANT; MALE; MEDULLOBLASTOMA; PHOSPHOPROTEIN PHOSPHATASES; RETROSPECTIVE STUDIES; TRANSFECTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 38049074854     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-007-9470-8     Document Type: Article

References (39)

1. Giangaspero F, Bigner SH, Giordana MT, Kleihues P, Trojanowski JQ (2000) Medulloblastoma. In: Kleihues P, Cavenee WK (eds) Pathology and genetics: Tumours of the nervous system. World Health Organization Classification of Tumours. International Agency for Research of Cancer, Lyon, France, pp 96-103
2. McNeil DE, Cote TR, Clegg L, Rorke LB (2002) Incidence and trends in pediatric malignancies medulloblastoma/primitive neuroectodermal tumor: a SEER update. Surveillance epidemiology and end results Med Pediatr Oncol 39:190-194
3. Rood BR, Macdonald TJ, Packer RJ (2004) Current treatment of medulloblastoma: Recent advances and future challenges. Semin Oncol 31:666-675
4. Biegel JA (1999) Cytogenetics and molecular genetics of childhood brain tumors. Neuro Oncol 1:139-151
5. Ellison D (2002) Classifying the medulloblastoma: Insights from morphology and molecular genetics. Neuropathol Appl Neurobiol 28:257-282
6. Cogen PH, McDonald JD (1996) Tumor suppressor genes and medulloblastoma. J Neurooncol 29:103-112
7. Benard J, Douc-Rasy S, Ahomadegbe JC (2003) TP53 family members and human cancers. Hum Mutat 21:182-191
8. Ohgaki H, Eibl RH, Wiestler OD, Yasargil MG, Newcomb EW, Kleihues P (1991) p53 mutations in nonastrocytic human brain tumors. Cancer Res 51:6202-6205
9. Saylors RL III, Sidransky D, Friedman HS, et al (1991) Infrequent p53 gene mutations in medulloblastomas. Cancer Res 51:4721-4723
10. Frank AJ, Hernan R, Hollander A, et al (2004) The TP53-ARF tumor suppressor pathway is frequently disrupted in large/cell anaplastic medulloblastoma. Brain Res Mol Brain Res 121:137-140
11. Eberhart CG, Chaudhry A, Daniel RW, Khaki L, Shah KV, Gravitt PE (2005) Increased p53 immunopositivity in anaplastic medulloblastoma and supratentorial PNET is not caused by JC virus. BMC Cancer 5:19
12. Wetmore C, Eberhart DE, Curran T (2001) Loss of p53 but not ARF accelerates medulloblastoma in mice heterozygous for patched. Cancer Res 61:513-516
13. Toledo F, Wahl GM (2006) Regulating the p53 pathway: In vitro hypotheses, in vivo veritas. Nat Rev Cancer 6:909-923
14. Adesina AM, Nalbantoglu J, Cavenee WK (1994) p53 gene mutation and mdm2 gene amplification are uncommon in medulloblastoma. Cancer Res 54:5649-5651
15. Batra SK, McLendon RE, Koo JS, et al (1995) Prognostic implications of chromosome 17p deletions in human medulloblastomas. J Neurooncol 24:39-45
16. Giordana MT, Duo D, Gasverde S, et al (2002) MDM2 overexpression is associated with short survival in adults with medulloblastoma. Neuro Oncol 4:115-122
17. Bulavin DV, Demidov ON, Saito S, et al (2002) Amplification of PPM1D in human tumors abrogates p53 tumor-suppressor activity. Nat Genet 31:210-215
18. Li J, Yang Y, Peng Y, et al (2002) Oncogenic properties of PPM1D located within a breast cancer amplification epicenter at 17q23. Nat Genet 31:133-134
19. Saito-Ohara F, Imoto I, Inoue J, et al (2003) PPM1D is a potential target for 17q gain in neuroblastoma. Cancer Res 63:1876-1883
20. Bulavin DV, Phillips C, Nannenga B, et al (2004) Inactivation of the Wip1 phosphatase inhibits mammary tumorigenesis through p38 MAPK-mediated activation of the p16(Ink4a)-p19(Arf) pathway. Nat Genet 36:343-350
21. Lu X, Nannenga B, Donehower LA (2005) PPM1D dephosphorylates Chk1 and p53 and abrogates cell cycle checkpoints. Genes Dev 19:1162-1174
22. Mendrzyk F, Radlwimmer B, Joos S, et al (2005) Genomic and protein expression profiling identifies CDK6 as novel independent prognostic marker in medulloblastoma. J Clin Oncol 23:8853-8862
23. Ehrbrecht A, Muller U, Wolter M, et al (2006) Comprehensive genomic analysis of desmoplastic medulloblastomas: Identification of novel amplified genes and separate evaluation of the different histological components. J Pathol 208:554-563
24. De Bortoli M, Castellino RC, Lu XY, et al (2006) Medulloblastoma outcome is adversely associated with overexpression of EEF1D, RPL30, and RPS20 on the long arm of chromosome 8. BMC Cancer 6:223
25. Verma RS, Babu A (eds) (1995) Human chromosomes: Principles and techniques. McGraw-Hill, New York, NY
26. Rauta J, Alarmo EL, Kauraniemi P, Karhu R, Kuukasjarvi T, Kallioniemi A (2006) The serine-threonine protein phosphatase PPM1D is frequently activated through amplification in aggressive primary breast tumours. Breast Cancer Res Treat 95:257-263
27. Rao PH, Murty VV, Gaidano G, Hauptschein R, Dalla-Favera R, Chaganti RS (1994) Subregional mapping of 8 single copy loci to chromosome 6 by fluorescence in situ hybridization. Cytogenet Cell Genet 66(4):272-273
28. el-Deiry WS, Tokino T, Velculescu VE, et al (1993) WAF1, a potential mediator of p53 tumor suppression. Cell 75:817-825
29. Tischer E, Mitchell R, Hartman T, et al (1991) The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. J Biol Chem 266:11947-11954
30. Takekawa M, Adachi M, Nakahata A, et al (2000) p53-inducible wip1 phosphatase mediates a negative feedback regulation of p38 MAPK-p53 signaling in response to UV radiation. EMBO J 19:6517-6526
31. Fiscella M, Zhang H, Fan S, et al (1997) Wip1, a novel human protein phosphatase that is induced in response to ionizing radiation in a p53-dependent manner. Proc Natl Acad Sci USA 94:6048-6053
32. Demidov ON, Kek C, Shreeram S, et al (2006) The role of the MKK6/p38 MAPK pathway in Wip1-dependent regulation of ErbB2-driven mammary gland tumorigenesis. Oncogene 26:2502-2506
33. Zhang X, Kim J, Ruthazer R, et al (2006) The HBP1 transcriptional repressor participates in RAS-induced premature senescence. Mol Cell Biol 26:8252-8266
34. Hirasawa A, Saito-Ohara F, Inoue J, et al (2003) Association of 17q21-q24 gain in ovarian clear cell adenocarcinomas with poor prognosis and identification of PPM1D and APPBP2 as likely amplification targets. Clin Cancer Res 9:1995-2004
35. Attardi LD, de VA, Jacks T (2004) Activation of the p53-dependent G1 checkpoint response in mouse embryo fibroblasts depends on the specific DNA damage inducer. Oncogene 23:973-980
36. Clifford B, Beljin M, Stark GR, Taylor WR (2003) G2 arrest in response to topoisomerase II inhibitors: The role of p53. Cancer Res 63:4074-4081
37. Nam C, Yamauchi H, Nakayama H, Doi K (2006) Etoposide induces apoptosis and cell cycle arrest of neuroepithelial cells in a p53-related manner. Neurotoxicol Teratol 28:664-672
38. Belova GI, Demidov ON, Fornace AJ Jr, Bulavin DV (2005) Chemical inhibition of Wip1 phosphatase contributes to suppression of tumorigenesis. Cancer Biol Ther 4:1154-1158
39. Yamaguchi H, Durell SR, Feng H, Bai Y, Anderson CW, Appella E (2006) Development of a substrate-based cyclic phosphopeptide inhibitor of protein phosphatase 2Cdelta, Wip1. Biochemistry 45:13193-13202